scholarly journals Successful treatment of extreme drug resistant Acinetobacter baumannii infection following a liver transplant

2020 ◽  
Vol 14 (04) ◽  
pp. 408-410 ◽  
Author(s):  
Muhammed Rasid Aykota ◽  
Tugba Sari ◽  
Sevda Yilmaz
Keyword(s):  
Liver Transplantation ◽  
Acinetobacter Baumannii ◽  
Blood Stream Infection ◽  
Organ Transplant ◽  
Drug Resistant ◽  
Biliary Leakage ◽  
Cadaveric Donor ◽  
Donor Liver Transplantation ◽  
Increased Risk ◽  
End Stage

Orthotopic liver transplantation is a life-saving procedure for patients with end-stage liver failure. However, Acinetobacter baumannii infections and acute rejection are important causes of morbidity and mortality following transplants. Here we present a case report of a cadaveric donor liver transplantation with infectious complications detected after transplantation. The patient was a 64-year-old female. Because of non-alcoholic steatohepatitis due to hepatic insufficiency (model for end-stage liver disease (MELD): 12; Child-Pugh: 9B), liver transplantation from a cadaveric donor was performed. Following the transplantation, the patient developed a blood stream infection, urinary tract infection (UTI) and postoperative wound infection from biliary leakage. A. baumannii was isolated from blood, urine and wound cultures. Imipenem (4×500 mg), tigecycline (2×50 mg) and phosphomycin (4×4 g) were administered intravenously (IV). On the 14th day of treatment, the bile fistula closed and there was no bacterial growth in blood and urine cultures. The patient was discharged with full recovery. The duration of a transplant patient’s hospital stay, intensive care unit stay, invasive interventions, blood transfusions and immunosuppressive treatments cause an increased risk of extensively drug-resistant (XDR) A. baumannii infections, and a high mortality rate is seen despite antibiotic treatment. Phosphomycin, used in combination therapy, may be an alternative in the treatment of XDR pathogens in organ transplant patients, due to its low side effect profile and lack of interaction with immunosuppressives.

scholarly journals Recurrent thrombosis of an arteriovenous fistula as a complication of COVID-19 in a chronic hemodialysis patient: A case report

2021 ◽  
pp. 112972982110008
Author(s):  
Joao Pedro Teixeira ◽  
Sara A Combs ◽  
Jonathan G Owen
Keyword(s):  
Arteriovenous Fistula ◽  
Hemodialysis Patient ◽  
Blood Stream Infection ◽  
Blood Stream ◽  
Chronic Hemodialysis ◽  
Risk Of Death ◽  
Catheter Directed Thrombolysis ◽  
Intravenous Heparin ◽  
Increased Risk ◽  
End Stage

Patients with end-stage kidney disease are at increased risk of death from coronavirus disease 2019 (COVID-19). In addition, severe COVID-19 has been associated with an increased risk of arterial and venous thromboses. In this report, we describe the case of a hemodialysis patient who developed an otherwise-unexplained thrombosis of an arteriovenous fistula during a symptomatic COVID-19 infection. Despite prompt treatment with three technically successful thrombectomies along with systemic intravenous heparin and two rounds of catheter-directed thrombolysis with tissue plasminogen activator, the fistula rapidly re-thrombosed each time and he required tunneled dialysis catheter placement. He subsequently required admission for hypoxemia from COVID-19 pneumonia and ultimately developed a catheter-related blood stream infection that likely contributed to his death. As the fistula had been previously well functioning and no angiographic explanation for the thrombosis was found, we speculate in this case the recurrent thromboses were related to the hypercoagulable state characteristic of severe COVID-19. Interventionalists performing hemodialysis access procedures should be aware of the prothrombotic state associated with COVID-19 and should consider it when deliberating how to best plan and approach access interventions in patients with symptomatic COVID-19.

Ethics of Liver Transplantation: The Role of the Anesthesiologist

2018 ◽  
Vol 22 (2) ◽  
pp. 229-236 ◽  
Author(s):  
James M. West
Keyword(s):  
Liver Transplantation ◽  
Organ Transplant ◽  
Donation After Circulatory Death ◽  
Donor Liver Transplantation ◽  
Definition Of Death ◽  
Life Saving ◽  
History Of ◽  
Definition Of ◽  
Related Liver Disease ◽  
Circulatory Death

Anesthesiologists have clearly established their place in the history of medical ethics. Our involvement goes back to 1966 when Henri Beecher published his landmark paper on research and informed consent. Participation in the ethics of transplantation is no less important than our previous work. Organ transplant has been life saving for many but also has given rise to many misunderstandings not just from the public but also among our own colleagues. These include methods of allocation and donation, the role that affluence may play in receiving an organ, the definition of death and donation after circulatory death. As perioperative physicians and important members of the transplant team, anesthesiologists are expected to participate in all aspects of care including ethical judgments. This article discusses some of the issues that seem to cause the most confusion and angst for those of us involved in both liver transplantation and in the procurement of organs. It will discuss the definition of death, donation after circulatory death, the anesthesiologists’ role on the selection committee, living donor liver transplantation, and transplantation of patients with alcohol-related liver disease.

Adult-to-Adult Living Donor Liver Transplantation: History, Current Practice, and Implications for the Future

2005 ◽  
Vol 15 (1) ◽  
pp. 36-44
Author(s):  
Claire Curran
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
The United States ◽  
Hepatitis C Infection ◽  
Donor Liver ◽  
Excessive Pressure ◽  
Donor Liver Transplantation ◽  
Number Of Patients ◽  
End Stage

More than 1600 Americans have received adult-to-adult living donor liver transplants. As the number of patients with end-stage liver disease is expected to grow significantly in the next 20 years due to hepatitis C infection, living donor liver transplantation has become a promising solution to the shortage of donor organs. The use of living donors provides organs in an environment of scarcity, allows patients to receive transplants when medically optimized, and produces liver segments with minimal ischemic damage. The donor complications most frequently cited in the medical literature include bile leaks and strictures, biloma, hepatic encephalopathy, wound infection, and pressure sores. In the wake of 2 donor deaths in the United States and subsequent media publicity, there have been new efforts by the transplant community to describe the risks and outcomes for donors, and establish safeguards to protect them from excessive pressure to donate.

Sign in / Sign up

Export Citation Format

Share Document